Thiogenesis Therapeutics Corp (TTIPF)

$2.58 +1.99 (340.05%)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 500
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 100%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. Its lead product candidate is TTI-0102, a prodrug that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and rett syndrome. The company is headquartered in Toronto, Canada.

Industry: Biotechnology
Sector: Healthcare
Phone: 888-223-9165
Address:
4 King Street West, Suite 401, Toronto, Canada
wavess
wavess Jun. 24 at 6:24 PM
$TTIPF June has marked a busy month for Thiogenesis Therapeutics, advancing its position as a leader in mitochondrial medicine with major clinical momentum this month across both sides of the Atlantic. TTI initiated a Phase 2a trial for Leigh Syndrome Spectrum in collaboration with the Children’s Hospital of Philadelphia (CHOP)—one of the world’s foremost centers in pediatric mitochondrial disorders: https://x.com/StckMasterFlash/status/1932861013423984766 Simultaneously, TTI is actively dosing patients in its Phase 2 trial for MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes) at clinical sites across Europe: https://x.com/StckMasterFlash/status/1922740812284055630
0 · Reply
wavess
wavess Jun. 23 at 6:33 PM
$TTIPF Held in collaboration with the Children’s Hospital of Philadelphia (CHOP), a global leader in pediatric mitochondrial care, Thiogenesis Therapeutics is advancing its lead candidate, TTI-0102, into a Phase 2a trial for Leigh Syndrome Spectrum (LSS). Notably, this is a landmark collaboration underscores the scientific strength behind TTI’s approach and marks a major step toward addressing a critical unmet medical need, as LSS is a devastating mitochondrial disorder with no approved therapies. Check out the full story here: https://x.com/StckMasterFlash/status/1932861013423984766
0 · Reply
wavess
wavess Jun. 20 at 7:35 PM
$TTIPF Thiogenesis Therapeutics has received FDA clearance to begin a Phase 2a trial of its lead candidate, TTI-0102, for the treatment of Leigh Syndrome Spectrum (LSS)—a rare, life-threatening mitochondrial disorder with no approved therapies: https://x.com/StckMasterFlash/status/1932861013423984766 Reflecting both the scientific credibility of Thiogenesis’ approach and the strong preclinical rationale for targeting oxidative stress in LSS patients, the trial will be held in collaboration with the Children’s Hospital of Philadelphia (CHOP), a globally recognized leader in pediatric mitochondrial medicine.
0 · Reply
newsfile_corp
newsfile_corp Jun. 20 at 1:01 PM
https://nfne.ws/256143 $TTIPF $TTI.TSXV #InvestmentBanking #OTC #OTCMarkets #OTCStocks #SmallCaps #TSXV #Investing
0 · Reply
wavess
wavess Jun. 19 at 6:18 PM
$TTIPF As U.S. clinical trials face growing delays, Thiogenesis Therapeutics is leveraging the EU’s more efficient framework to accelerate enrollment and generate early efficacy data, having activated its second clinical site in France for its ongoing Phase 2 trial of TTI-0102 in MELAS patients—highlighting the strategic advantage of conducting rare disease trials in Europe: https://x.com/StckMasterFlash/status/1935049659816214802 With streamlined regulatory pathways, faster site activation, and greater scientific collaboration, Europe is proving to be an increasingly attractive jurisdiction for clinical-stage biotech companies. Now with multiple active sites across France and the Netherlands, and interim results expected in September 2025, TTI is gaining momentum in a market known for supporting high-unmet-need orphan drug development. Posted on Behalf of Thiogenesis Therapeutics Corp.
0 · Reply
wavess
wavess Jun. 18 at 6:29 PM
$TTIPF Yesterday, Thiogenesis Therapeutics (TTI.v TTIPF) announced it has activated its second clinical site in France for the Phase 2 trial of TTI-0102, a next-gen thiol-based therapy for MELAS—a rare and devastating mitochondrial disease: https://x.com/StckMasterFlash/status/1935049659816214802 On track for key data readouts by September 2025, this expansion highlights both the growing momentum behind TTI-0102 and the strategic advantage of conducting trials in Europe’s increasingly efficient regulatory landscape for orphan diseases, over the US FDA. $MNPR $XENE
0 · Reply
wavess
wavess Jun. 17 at 6:54 PM
$TTIPF Today, Thiogenesis Therapeutics, a clinical-stage biotech, has announced the activation of its second clinical site in France for the ongoing Phase 2 trial of its lead candidate, TTI-0102, in patients with MELAS, marking a key expansion milestone for the multicenter European study: https://www.newsfilecorp.com/release/255687/Thiogenesis-Announces-Second-Site-Begins-Enrolling-in-Phase-2-MELAS-Clinical-Trial-and-Provides-Update The randomized, double-blind, placebo-controlled, multi-country and multi-center trial is active in Europe and marks a major milestone for the company, bringing a potential treatment to "one of the most prevalent and debilitating of the inherited mitochondrial diseases for which there are no approved drugs in the EU or the U.S." This update follows TTI receiving FDA clearance to launch a Phase 2a trial for TTI-0102 in Leigh Syndrome Spectrum with the Children's Hospital of Philadelphia—a rare, life-threatening mitochondrial disorder with no approved treatments. More info: https://x.com/StckMasterFlash/status/1932861013423984766
0 · Reply
newsfile_corp
newsfile_corp Jun. 17 at 1:01 PM
https://nfne.ws/255687 $TTIPF $TTI.TSXV #InvestmentBanking #OTC #OTCMarkets #OTCStocks #SmallCaps #TSXV #Investing
0 · Reply
wavess
wavess Jun. 13 at 4:58 PM
$TTIPF Marks a pivotal moment in affirming the scientific and clinical promise of its lead candidate, Thiogenesis Therapeutics received FDA clearance to launch a Phase 2a trial for TTI-0102 in Leigh Syndrome Spectrum—a rare, life-threatening mitochondrial disorder with no approved treatments: https://x.com/StckMasterFlash/status/1932861013423984766 This approval is a critical endorsement, especially given the early-stage nature of the asset and the disease's high unmet need; validating TTI's approach of targeting oxidative stress via intracellular cysteine and glutathione elevation and signalling confidence in the safety and potential efficacy of TTI-0102, which is additionally in clinical trials in Europe for MELAS.
0 · Reply
wavess
wavess Jun. 12 at 4:11 PM
$TTIPF Yesterday, Thiogenesis Therapeutics announced it has received FDA clearance to launch a Phase 2a trial for TTI-0102 in Leigh Syndrome Spectrum—a rare, life-threatening mitochondrial disorder with no approved treatments. Backed by leading experts at Children’s Hospital of Philadelphia, a leader in pediatric mitochondrial medicine, serving as the lead clinical site, and strong preclinical data, the study will assess TTI-0102’s potential to reduce oxidative stress and improve quality of life for patients. This milestone marks a major step toward addressing a critical unmet medical need and positions TTI for potential breakthrough therapy designation - in addition to TTI's current Phase 2 clinical trial in Europe for MELAS, another rare pediatric mitochondrial disease that currently has no approved treatment. Check out the full story here: https://x.com/StckMasterFlash/status/1932861013423984766
0 · Reply
Latest News on TTIPF
No data available.
wavess
wavess Jun. 24 at 6:24 PM
$TTIPF June has marked a busy month for Thiogenesis Therapeutics, advancing its position as a leader in mitochondrial medicine with major clinical momentum this month across both sides of the Atlantic. TTI initiated a Phase 2a trial for Leigh Syndrome Spectrum in collaboration with the Children’s Hospital of Philadelphia (CHOP)—one of the world’s foremost centers in pediatric mitochondrial disorders: https://x.com/StckMasterFlash/status/1932861013423984766 Simultaneously, TTI is actively dosing patients in its Phase 2 trial for MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes) at clinical sites across Europe: https://x.com/StckMasterFlash/status/1922740812284055630
0 · Reply
wavess
wavess Jun. 23 at 6:33 PM
$TTIPF Held in collaboration with the Children’s Hospital of Philadelphia (CHOP), a global leader in pediatric mitochondrial care, Thiogenesis Therapeutics is advancing its lead candidate, TTI-0102, into a Phase 2a trial for Leigh Syndrome Spectrum (LSS). Notably, this is a landmark collaboration underscores the scientific strength behind TTI’s approach and marks a major step toward addressing a critical unmet medical need, as LSS is a devastating mitochondrial disorder with no approved therapies. Check out the full story here: https://x.com/StckMasterFlash/status/1932861013423984766
0 · Reply
wavess
wavess Jun. 20 at 7:35 PM
$TTIPF Thiogenesis Therapeutics has received FDA clearance to begin a Phase 2a trial of its lead candidate, TTI-0102, for the treatment of Leigh Syndrome Spectrum (LSS)—a rare, life-threatening mitochondrial disorder with no approved therapies: https://x.com/StckMasterFlash/status/1932861013423984766 Reflecting both the scientific credibility of Thiogenesis’ approach and the strong preclinical rationale for targeting oxidative stress in LSS patients, the trial will be held in collaboration with the Children’s Hospital of Philadelphia (CHOP), a globally recognized leader in pediatric mitochondrial medicine.
0 · Reply
newsfile_corp
newsfile_corp Jun. 20 at 1:01 PM
https://nfne.ws/256143 $TTIPF $TTI.TSXV #InvestmentBanking #OTC #OTCMarkets #OTCStocks #SmallCaps #TSXV #Investing
0 · Reply
wavess
wavess Jun. 19 at 6:18 PM
$TTIPF As U.S. clinical trials face growing delays, Thiogenesis Therapeutics is leveraging the EU’s more efficient framework to accelerate enrollment and generate early efficacy data, having activated its second clinical site in France for its ongoing Phase 2 trial of TTI-0102 in MELAS patients—highlighting the strategic advantage of conducting rare disease trials in Europe: https://x.com/StckMasterFlash/status/1935049659816214802 With streamlined regulatory pathways, faster site activation, and greater scientific collaboration, Europe is proving to be an increasingly attractive jurisdiction for clinical-stage biotech companies. Now with multiple active sites across France and the Netherlands, and interim results expected in September 2025, TTI is gaining momentum in a market known for supporting high-unmet-need orphan drug development. Posted on Behalf of Thiogenesis Therapeutics Corp.
0 · Reply
wavess
wavess Jun. 18 at 6:29 PM
$TTIPF Yesterday, Thiogenesis Therapeutics (TTI.v TTIPF) announced it has activated its second clinical site in France for the Phase 2 trial of TTI-0102, a next-gen thiol-based therapy for MELAS—a rare and devastating mitochondrial disease: https://x.com/StckMasterFlash/status/1935049659816214802 On track for key data readouts by September 2025, this expansion highlights both the growing momentum behind TTI-0102 and the strategic advantage of conducting trials in Europe’s increasingly efficient regulatory landscape for orphan diseases, over the US FDA. $MNPR $XENE
0 · Reply
wavess
wavess Jun. 17 at 6:54 PM
$TTIPF Today, Thiogenesis Therapeutics, a clinical-stage biotech, has announced the activation of its second clinical site in France for the ongoing Phase 2 trial of its lead candidate, TTI-0102, in patients with MELAS, marking a key expansion milestone for the multicenter European study: https://www.newsfilecorp.com/release/255687/Thiogenesis-Announces-Second-Site-Begins-Enrolling-in-Phase-2-MELAS-Clinical-Trial-and-Provides-Update The randomized, double-blind, placebo-controlled, multi-country and multi-center trial is active in Europe and marks a major milestone for the company, bringing a potential treatment to "one of the most prevalent and debilitating of the inherited mitochondrial diseases for which there are no approved drugs in the EU or the U.S." This update follows TTI receiving FDA clearance to launch a Phase 2a trial for TTI-0102 in Leigh Syndrome Spectrum with the Children's Hospital of Philadelphia—a rare, life-threatening mitochondrial disorder with no approved treatments. More info: https://x.com/StckMasterFlash/status/1932861013423984766
0 · Reply
newsfile_corp
newsfile_corp Jun. 17 at 1:01 PM
https://nfne.ws/255687 $TTIPF $TTI.TSXV #InvestmentBanking #OTC #OTCMarkets #OTCStocks #SmallCaps #TSXV #Investing
0 · Reply
wavess
wavess Jun. 13 at 4:58 PM
$TTIPF Marks a pivotal moment in affirming the scientific and clinical promise of its lead candidate, Thiogenesis Therapeutics received FDA clearance to launch a Phase 2a trial for TTI-0102 in Leigh Syndrome Spectrum—a rare, life-threatening mitochondrial disorder with no approved treatments: https://x.com/StckMasterFlash/status/1932861013423984766 This approval is a critical endorsement, especially given the early-stage nature of the asset and the disease's high unmet need; validating TTI's approach of targeting oxidative stress via intracellular cysteine and glutathione elevation and signalling confidence in the safety and potential efficacy of TTI-0102, which is additionally in clinical trials in Europe for MELAS.
0 · Reply
wavess
wavess Jun. 12 at 4:11 PM
$TTIPF Yesterday, Thiogenesis Therapeutics announced it has received FDA clearance to launch a Phase 2a trial for TTI-0102 in Leigh Syndrome Spectrum—a rare, life-threatening mitochondrial disorder with no approved treatments. Backed by leading experts at Children’s Hospital of Philadelphia, a leader in pediatric mitochondrial medicine, serving as the lead clinical site, and strong preclinical data, the study will assess TTI-0102’s potential to reduce oxidative stress and improve quality of life for patients. This milestone marks a major step toward addressing a critical unmet medical need and positions TTI for potential breakthrough therapy designation - in addition to TTI's current Phase 2 clinical trial in Europe for MELAS, another rare pediatric mitochondrial disease that currently has no approved treatment. Check out the full story here: https://x.com/StckMasterFlash/status/1932861013423984766
0 · Reply
newsfile_corp
newsfile_corp Jun. 12 at 2:02 PM
https://nfne.ws/255359 $TTIPF $TTI.TSXV #InvestmentBanking #OTC #OTCMarkets #OTCStocks #SmallCaps #TSXV #Investing
0 · Reply
wavess
wavess Jun. 11 at 6:07 PM
$TTIPF Today, Thiogenesis Therapeutics announced that it has received FDA clearance to initiate a Phase 2a clinical trial for its lead candidate, TTI-0102, in Leigh Syndrome Spectrum—a rare and life-threatening pediatric mitochondrial disease. The Phase 2a clinical trial is expected to begin in H2 2025, with the Children’s Hospital of Philadelphia (CHOP), a leader in pediatric mitochondrial medicine, serving as the lead clinical site. This trial will run in addition to TTI's current Phase 2 clinical trial in Europe for MELAS, another rare pediatric mitochondrial disease that currently has no approved treatment. Full Breakdown Here: https://x.com/StckMasterFlash/status/1932861013423984766
0 · Reply
newsfile_corp
newsfile_corp Jun. 11 at 1:00 PM
https://nfne.ws/255101 $TTIPF $TTI.TSXV #InvestmentBanking #OTC #OTCMarkets #OTCStocks #SmallCaps #TSXV #Investing
0 · Reply
wavess
wavess Jun. 10 at 6:03 PM
$TTIPF Backed by orphan drug designation and now entering a Phase 2 clinical trial in Europe, Thiogenesis Therapeutics is advancing a breakthrough therapy for a rare pediatric mitochondrial disease that currently has no approved treatment: https://x.com/StckMasterFlash/status/1922740812284055630 With a seasoned leadership team, and regulatory momentum on its side, TTI is positioning itself at the intersection of rare disease innovation and market opportunity.
0 · Reply
wavess
wavess Jun. 9 at 4:59 PM
$TTIPF With a fast-track regulatory path, data expected by fall, and a platform targeting multiple billion-dollar orphan indications, Thiogenesis Therapeutics (TTI.v TTIPF) has officially entered Phase 2 with TTI-0102 for MELAS—a rare, life-altering mitochondrial disease with no approved treatments. Significantly, this positions the company for a major valuation rerate opportunity as it advances one of the most de-risked Phase 2 programs in biotech. More info here: https://x.com/StckMasterFlash/status/1922740812284055630
0 · Reply
wavess
wavess Jun. 5 at 8:35 PM
$TTIPF Major milestone for under the radar biotech- Thiogenesis Therapeutics just dosed its first patients in a Phase 2 trial for MELAS—a devastating mitochondrial disease with no approved treatments in the U.S. or EU. Here’s why this could be a rerating moment for the stock: https://x.com/StckMasterFlash/status/1922740812284055630
0 · Reply
CalculatedSwing
CalculatedSwing Jun. 3 at 12:19 AM
$TTIPF what have I stumbled upon..
0 · Reply
wavess
wavess Jun. 2 at 9:54 PM
$TTIPF Thiogenesis Therapeutics has initiated its Phase 2 clinical trial of TTI-0102 for MELAS, a rare mitochondrial disorder with no approved treatments, to evaluate the safety, efficacy, and quality-of-life outcomes over six months: https://x.com/StckMasterFlash/status/1922740812284055630 With a streamlined 505(b)(2) and EU hybrid regulatory path, interim data expected this fall, and a market valuation well below peers, the trial marks a critical inflection point for TTI.
0 · Reply
wavess
wavess May. 30 at 7:47 PM
$TTIPF In a biotech landscape filled with early-stage candidates, Thiogenesis Therapeutics is moving forward with a Phase 2 trial for MELAS, a rare mitochondrial disorder with no approved treatments. With orphan drug status, a 505(b)(2) pathway, and supportive clinical precedent, TTI is advancing a targeted approach in a space with limited competition and high unmet need, positioning itself for a potential rerating as results approach. Check out the latest update here: https://x.com/StckMasterFlash/status/1922740812284055630
0 · Reply
wavess
wavess May. 28 at 9:11 PM
$TTIPF Thiogenesis Therapeutics has officially entered Phase 2 with TTI-0102 for MELAS—a rare, devastating mitochondrial disease with no approved treatments in the U.S. or EU: https://x.com/StckMasterFlash/status/1922740812284055630 Backed by orphan drug potential, a de-risked regulatory path, and early human data showing strong tolerability, TTI is now on track for a pivotal interim readout this fall—setting the stage for a major valuation inflection.
0 · Reply
wavess
wavess May. 27 at 8:09 PM
$TTIPF Focused on an addressable market estimated to exceed $1 billion globally, Thiogenesis Therapeutics is a clinical-stage biotech developing breakthrough treatments for mitochondrial diseases — devastating conditions with no approved therapies. Having just entered a Phase 2 trial for MELAS, a rare genetic disorder that causes progressive neurological decline, TTI is targeting a de-risked regulatory pathway with promising early data, in a market where peer companies trade at valuations 10x higher. More info here: https://x.com/StckMasterFlash/status/1922740812284055630 Posted on Behalf of Thiogenesis Therapeutics Corp.
0 · Reply
wavess
wavess May. 14 at 7:50 PM
$TTIPF Today, Clinical-stage biotech company Thiogenesis Therapeutics announced the dosing the first two patients in its Phase 2 clinical trial of TTI-0102 for MELAS, a rare and debilitating mitochondrial disease. The randomized, double-blind, placebo-controlled, multi-country and multi-center trial is active in Europe and marks a major milestone for the company, bringing a potential treatment to "one of the most prevalent and debilitating of the inherited mitochondrial diseases for which there are no approved drugs in the EU or the U.S." Notably, entry into Phase 2 itself significantly raises company valuations as comparable biotech firms average US$249M in valuation (~15x TTI's current valuation). For more information, refer to this mews & company breakdown: https://x.com/StckMasterFlash/status/1922740812284055630
0 · Reply